VMY-1-103

• Description :

  A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.

• Stability :

  ≥ 2 years

• Purity :

  >98% (HPLC)

• Weight :

  708.27

• Molecular Formula :

  C34H42ClN9O4S

• Notes :

  Research use only, not for human use.

• Receptor :

  CDK

• CAS Number :

  1209002-43-6